Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Design Therapeutics, Inc. - Common Stock (NQ:DSGN)

8.935 -0.685 (-7.12%)
Streaming Delayed Price Updated: 2:51 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Design Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Design Therapeutics to Participate in Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Justin Gover to Board of Directors
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.